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Background: Age-associated memory impairment (AAMI) and mild cognitive impairment (MCI) were considered to have a positive 
correlation with early dementia status, reflecting the decline in objective cognitive function. Studies results exploring the character-
istics of AAMI and MCI remain mixed. We investigated the characteristics of AAMI and MCI using neuroimaging and neurocognitive 
function in healthy Korean adults.
Methods: This cross-sectional study analyzed a total of 14 participants who visited single health promotion center. AAMI and 
MCI was defined via questionnaires. Participants were classified into three groups based on neurocognitive status: normal, AAMI, 
MCI. We conducted either Kruskal-Wallis or chi-square test to compare the neuroimaging characteristics between three groups; 
Mann-Whitney U test was applied for the within-group analysis. Kruskal-Wallis test was used to investigate the neurocognitive 
function between three groups.
Results: In the case of AAMI and MCI, there were partial metabolic decreases in various parts such as temporal lobe, frontal 
lobe, parietal lobe and cerebellum. Profound disparities in metabolic decrease in parietal lobe were observed among three groups 
(P=0.049). In the MMSE characteristics, MCI group showed marked deterioration in attention (P=0.030), and decreased in more 
various cognitive domains than AAMI group.
Conclusion: The distinct neuroimaging characteristics were observed among three groups. The deficit of neurocognitive function 
was more prominent in attention in MCI group.
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INTRODUCTION
The average life span of modern people has been ex-
tended, while cognitive function-related degenerative diseases 
such as vascular dementia and Alzheimer's dementia have in-
creased [1]. However, the clear cause of cognitive decline 
has not been clarified yet, so the interest and concern of the 
medical community are increasing on the methods for cogni-
tive function preservation [2].
Age-associated memory impairment (AAMI) is a diag-
nostic term that applies to healthy people aged 50 years or 
older who have experienced gradual memory impairment [3]. 
Although they have fewer behavioral disabilities compared to 
cognitive disorders such as Alzheimer's disease, it refers to a 
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state of considerable difficulty in living for the elderly. There 
is also a similar definition of subjective memory impairment 
(SMI). These age-related subjective memory disorders have 
been considered to reflect a decline in objective cognitive 
function and to be associated with early dementia, but some 
studies have shown that subjective memory disorders is more 
associated with depression, anxiety, personality and education 
than emotional cognitive decline [4-6].
Mild cognitive impairment (MCI) is a broad concept that 
refers to the intermediate stage between normal aging and 
dementia. Therefore, the patient can be defined as MCI 
when there are complaints about memory deterioration by the 
patient or caregiver report, good activities of daily living, nor-
mal cognitive ability, abnormal memory, but not dementia 
[7]. Approximately 80% of patients with MCI develop into 
dementia within 10 years, and unlike dementia, neurons are 
not yet destroyed, which is a clinically important period for 
reversible changes [8]. According to an empirical study on 
MCI, symptoms of early memory impairment are related to 
neuro-pathologic changes in the limbic system and eventually 
to Alzheimer’s disease, but the accumulation of research is 
insufficient [9,10]. 
Currently, screening and intervention at the pre-dementia 
stage are known to be the best way to prevent dementia, but 
the controversy about the linkage between AAMI or MCI 
and dementia continues [11]. Therefore, the relationship and 
the difference between AAMI and MCI should be clarified 
to be helpful for appropriate prevention and treatment of pa-
tients who suffered from memory impairment depending on 
the status. Our study aimed to investigate the characteristics 
of each of AAMI and MCI and compared neurocognitive 
function in healthy Korean adults.
MATERIALS AND METHODS
1. Survey overview and study population
We retrospectively reviewed the medical records of 23 par-
ticipants aged ≥50 years old who voluntarily visited the 
Family medicine of Gangnam Severance Hospital between 
October 2017 and August 2018 for assessments of neuro-
cognitive health status. This study was conducted in accord-
ance with the ethical principles of the Declaration of Helsinki 
and was approved by the Institutional Review Board of Yonsei 
University College of Medicine, Gangnam Severance Hospital, 
Seoul, Korea. We excluded 9 subjects who reported physical 
and psychiatric problems related to cognitive dysfunction such 
as major depressive disorder, severe deterioration in activities 
of daily living, diagnosis of Alzheimer’s dementia and missing 
data in questionnaires. Finally, a total of 14 participants were 
analyzed in this study. 
2. Assessments of anthropometric and laboratory 
data 
Physical examinations were performed by medical staff ac-
cording to a standard protocol. Body weight (kg) and height 
(cm) were measured in light indoor clothing and without 
shoes to the nearest 0.1 kg and 0.1cm, respectively. Body 
mass index (BMI) was calculated as weight in kilograms 
(kg) divided by height in meters squared (m2). Blood pres-
sure was obtained with the participant in the sitting position 
after 5 minutes of rest using an automated device 
(TM-2665P, A&D Co., LTD., Tokyo, Japan). Venous blood 
sampling was performed after a 12h fasting period. Fasting 
plasma glucose, total cholesterol, triglyceride, high-density lip-
oprotein (HDL), and low-density lipoprotein (LDL) choles-
terol were measured using a Hitachi 7600-110 chemistry au-
to-analyzer (Hitachi, Tokyo, Japan). Serum fasting insulin 
levels and C-reactive protein, serum total vitamin D were 
measured using a chemiluminescence immunoassay system 
(Roche, Indianapolis, IN, USA). Homocysteine measurement 
was determined using a commercially available enzymatic col-
orimetric assay AU5800 (Beckman Coulter, Irvine, CA, 
USA), and the values were expressed in mol/L. Information 
about lifestyle behaviors, including cigarette smoking, alcohol 
consumption, and physical activity, was obtained by a self-ad-
ministered questionnaire. Educational level was classified as 
either middle school or below, high school, and college or 
above. Current smokers were defined as individuals who cur-
rently smoke. Physical activity was defined as exercise more 
than 30 minutes in duration and more than two or three 
times per week and alcohol drinking as drink any kind of al-
cohol more than once a month. Diabetes mellitus, hyper-
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Trend 1 vs. 2 1 vs. 3 2 vs. 3
Age (years)  64.0±1.3  65.8±1.6  73.7±1.6 0.562 0.739 0.154 0.827
Women 2 (66.7) 6 (85.7) 3 (75.0) 0.781 0.490 0.809 0.658
MoCA  28.3±1.2  26.3±1.9  26.3±3.1 0.271 0.104 0.271 0.772
K-MMSE  28.3±0.6  29.3±0.8  26.5±0.6 0.008 0.090 0.029 0.007
MAC-Q   9.7±3.1  20.4±8.2  17.8±5.7 0.071 0.039 0.048 0.634
SMCQ   1.7±1.2   5.3±3.6   4.8±4.1 0.236 0.084 0.285 0.704
Weight (kg)  52.8±13.9  61.2±8.1  57.4±14.3 0.759 0.424 0.724 0.850
BMI (kg/m2)  19.8±2.5  22.4±2.8  23.7±4.1 0.318 0.305 0.157 0.450
SBP (mmHg) 120.0±24.0 120.8±12.3 148.3±13.5 0.086 0.739 0.165 0.033
DBP (mmHg)  68.5±23.3  70.7±6.6  80.8±7.4 0.217 1.000 0.643 0.051
Glucose (mg/dL)  93.7±12.7 103.4±14.1  102±2.8 0.422 0.819 0.212 0.298
Total cholesterol (mg/dL) 166.7±23.1 208.6±36.4 187.0±42.5 0.181 0.087 0.724 0.218
Triglyceride (mg/dL)  72.3±45.7 131.9±43.4 146.3±101.4 0.293 0.138 0.289 0.571
HDL cholesterol (mg/dL)  59.7±19.0 58.9±12.1  60.5±26.3 0.988 0.909 0.857 1.000
LDL cholesterol (mg/dL) 104.7±9.3 140.7±39.1 122.8±30.1 0.203 0.053 0.480 0.571
Hs-CRP (mg/dl)   0.2±0.0   1.6±2.4   3.1±5.2 0.124 0.073 0.060 0.635
Insulin (U/mL)   4.1±4.8   5.5±4.2  10.0±6.3 0.445 0.439 0.355 0.327
Vitamin D (ng/mL)  16.1±8.5  22.9±14.5  23.9±10.0 0.633 0.439 0.355 0.806
Homocysteine (mol/L)   6.4±1.3   6.6±1.6   7.4±1.6 0.562 0.739 0.355 0.394
Hypertension (%) 0 (0.0) 1 (14.3) 4 (100) 0.006 0.490 0.008 0.006
Diabetes mellitus (%) 0 (0.0) 2 (28.6) 1 (25.0) 0.588 0.301 0.350 0.898
Dyslipidemia (%) 0 (0.0) 4 (57.1) 2 (50) 0.233 0.091 0.147 0.819
Physical activity (%) 1 (33.3) 1 (14.3) 1 (25) 0.296 0.240 0.350 0.308
Current smoker (%) 0 (0.0) 0 (0.0) 0 (0.0) - - - -
Alcohol drinking (%) 0 (0.0) 3 (42.9) 2 (50) 0.337 0.175 0.147 0.819
MEQ  58.0±6.1  50.4±15.5  54.0±4.0 0.859 0.819 0.463 0.575
Education (years)  14.7±2.3  14.9±2.0  16.0±0.0 0.486 0.886 0.248 0.260
Data are expressed as the mean±standard deviation or number (percentage).
Physical activity means moderate intensity physical exercise (two or more times/week). Alcohol drinking means drinking any kinds of alcohol
≥once a month. Data are expressed as the mean±standard deviation or percentage. 
AAMI, age related memory impairment; MCI, mild cognitive impairment; MoCA, Montréal cognitive functional assessment; K-MMSE,
Korean mini-mental state exam; MAC-Q, memory assessment clinic-questionnaire; SMCQ, subjective memory complaint questionnaire; 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; Hs-CRP, high sensitivity C-reactive protein; MEQ, morningness-eveningness questionnaire.
tension, and dyslipidemia was defined as taking medication, 
or diagnosis by physicians. 
3. Definition of AAMI and MCI
To date, the assessment questionnaire for AAMI is the 
memory assessment clinic-questionnaire (MAC-Q), which is 
the most concise statement of AAMI. MAC-Q consists of 6 
items, each of which can be answered on a scale of 1 to 5 
points and a total score of 30 points. The higher the score, 
the more the participants feel difficulty about their memory. 
If at least one of the 4 or 5 points is recorded, it will be de-
fined as AAMI [12]. Since there is no official Korean ver-
sion of MAC-Q, we made a translation in cooperation with 
the Korean translation institute, and we need to study for val-
idation with a large sample size. We defined AAMI as 4 or 
5 points in at least one item in MAC-Q, Korean mini-mental 
state exam (K-MMSE) score of 27 points or more and 
Korean activities of daily living (K-ADL) as a group with no 
serious dysfunctions. A similar concept of AAMI is SMI, 
which uses the subjective memory complaint questionnaire as 
a tool to assess it in Korea. If the score is 6 or more out of 
14 points, it is recommended to consult the doctor [13].
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Table 2. Comparisons of decreased foci detected by brain 
positron emission tomography/computed tomography between 








Temporal lobe 0 (0.0) 2 (40.0) 1 (25.0) 0.557
Frontal lobe 1 (50.0) 1 (20.0) 1 (25.0) 0.717
Cerebellum 0 (0.0) 1 (20.0) 0 (0.0) 0.517
Parietal lobe 1 (50.0) 1 (20.0) 1 (25.0) 0.049
No foci 1 (50.0) 2 (40.0) 1 (25.0) 0.814
Data are expressed as the number (percentage).
AAMI, age related memory impairment; MCI, mild cognitive 
impairment. 
In the diagnostic criteria proposed by Petersen et al., MCI 
has a memory impairment in the caregiver and the patient 
and shows objectively decreased memory compared to the age, 
but the overall cognitive function should be preserved [14]. 
Therefore, we defined MCI as a group that received 4 or 5 
points in at least one item in MAC-Q, K-MMSE score of 
24 or more, and no severe dysfunction in K-ADL. There is 
a Montréal cognitive functional assessment (MoCA), which is 
known to be useful for assessing MCI, and we also used this 
questionnaire as an additional tool in this study [15]. 
Morningness-eveningness questionnaire is useful to assess the 
sleep/wake cycle or circadian patterns of human [16].
4. Acquisition of positron emission tomography/ 
computed tomography (PET/CT) 
In all subjects, Brain CT and 18F-fluorodeoxyglucose 
(FDG) PET scans, which is known to be a helpful diag-
nostic tool for suspicion of early stage of cognitive impair-
ment, were performed with a Biograph 40 True Point 
PET/CT scanner (Siemens Medical Solutions; Malvern, PA, 
USA) [17]. Fifty minutes after intravenous injection of 
375.0±89.5 MBq of 18F-FDG, PET/CT was performed. A 
head holder was applied to minimize the head motion during 
the scan. After brain CT scan for attenuation correction, 
structural imaging (120 KeV, 180 mAs, and 3 mm of slice 
thickness), and 10 minutes of emission scan, 3D CT and 
PET images were reconstructed in 512×512×110 matrix 
with 0.668×0.668×2 mm voxel size the 18F-FDG PET scan 
to identify those people with MCI who would develop 
Alzheimer’s disease dementia or other forms of dementia over 
a period of time.
5. Statistical analysis
Participants were classified into normal, AAMI, and MCI 
groups according to their memory impairment status. Comparison 
of characteristics of the study population between three cate-
gories in the field using chi-square, or Kruskal-Wallis test ac-
cording to the condition. The results were expressed as mean 
and standard deviation (SD) or percentage for quantitative 
variables. Chi square analysis was performed to compare the 
lesions of the three groups with brain PET/CT, and 
Kruskal-Wallis test was calculated to assess comparisons of 
cognitive functions categorized by K-MMSE and MoCA. 
All analyses were conducted using SPSS version 23.0 stat-
istical software (SPSS version 23.0; IBM Corp., Armonk, 
NY, USA). Statistical significance was determined at a P-val-
ue＜0.05.
RESULTS 
Table 1 shows the demographic and biochemical character-
istics of the participants in relation to memory impairment 
status. The mean values of several metabolic variables, 
weight, fasting glucose, and cholesterol tend to be higher in 
the AAMI group than in the normal and MCI group, stat-
istically not significant. Only the LDL cholesterol was stat-
istically significantly higher in the AAMI group. Other meta-
bolic variables, BMI, fasting insulin, triglyceride and homo-
cysteine were the higher in the MCI group than in the nor-
mal and AAMI group. Table 2, Figure 1 and 2 illustrates 
the decreased foci detected by brain PET/CT between nor-
mal and AAMI group. In the case of AAMI, there were no 
specific findings on brain PET/CT in two subjects and parti-
al metabolic decrease was observed in various parts such as 
temporal lobe, frontal lobe and cerebellum. In the MCI 
group, one patient had decreased metabolism in the parietal 
lobe, one in the temporal lobe, and one in the frontal lobe. 
The difference between the MCI and AAMI groups was 
statistically significant in the parietal lobe. Table 3 and Table 
4 show the results of Kruskal-Wallis test to compare the cat-
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Figure 1. A composite picture of 
glucose metabolism using positron
emission tomography and the 
tracer fluorodeoxyglucose. Patient
with age-associated memory im-
pairment on the right shows 
reduced glucose metabolism in the
bilateral frontal lobes and left 
temporal lobe. There is also de-
creased uptake in right parietal 
and temporal lobes with lesser 
degree, and slightly increased 
uptake in right basal ganglia.
Figure 2. Comparisons of decreased foci detected by brain positron emission tomography/computed tomography between age 
associated memory impairment (AAMI) and mild cognitive impairment (MCI) groups. The AAMI patient  (A) shows moderately decreased
glucose metabolism in the cerebellum and mild degree of decreased uptake in bilateral inferior temporal lobes. Another AAMI patient
(B) shows focal glucose hypometabolism in right parietal lobe: Probably partial volume effect or atrophy (sulcus widening). The MCI
patient (C) shows mild degree of glucose hypometabolism in both frontal lobes and insula.
egories of neurocognitive function with K-MMSE and 
MoCA among the three groups, and MCI group showed 
marked deterioration of in attention (P value=0.030), and 
decreased neurocognitive function in more various domains 
than AAMI group with K-MMSE. 
DISCUSSION
In this study, we found that mean values of several meta-
bolic parameters, such as LDL cholesterol, BMI, fasting in-
sulin, triglyceride and homocysteine were the higher in the 
AAMI and MCI group than normal group. MCI group 
showed a significant metabolic reduction in the parietal lobe 
and decreased function in more various domains than AAMI 
group. These findings mean MCI group had more delete-
rious cognitive function and could develop into the dementia. 
Previous study showed that 15% of patients diagnosed with 
MCI proceeded to dementia annually, which supported our 
result. Interestingly, AAMI also correlated with metabolic pa-
rameters, such as weight, fasting glucose, total cholesterol and 
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Place (5) 5.00±0.00 5.00±0.00 4.25±0.96 0.068
Time (5) 5.00±0.00 5.00±0.00 4.75±0.50 0.287
Memory (3) 3.00±0.00 3.00±0.00 3.00±0.00 1.000
Attention (5) 4.00±1.00 5.00±0.00 3.75±0.96 0.030
Recall (3) 2.33±0.58 2.29±0.76 2.25±0.96 1.000
Language, visuospatial (9) 9.00±0.00 9.00±0.00 8.75±0.27 0.287
Data are expressed as the mean±standard deviation.
AAMI, age related memory impairment; MCI, mild cognitive impairment.








Visuopatial Executive (5) 4.67±0.58 5.00±0.00 4.50±1.00 0.337
Naming (3) 3.00±0.00 2.57±0.53 2.75±0.50 0.409
Attention (6) 6.00±0.00 5.57±0.53 5.25±0.50 0.161
Language (3) 3.00±1.00 2.71±0.49 3.00±0.00 0.338
Abstraction (2) 2.00±0.00 1.71±0.76 1.50±1.00 0.666
Delayed recall (5) 3.67±1.53 2.29±2.36 3.00±1.41 0.637
Orientation (6) 6.00±0.00 6.00±0.00 6.00±0.00 1.000
Data are expressed as the mean±standard deviation.
AAMI, age related memory impairment; MCI, mild cognitive impairment.
LDL cholesterol, however, the foci of decreased metabolism 
in the brain was different from MCI group. To date, only a 
few researchers have reported the difference between AAMI 
and MCI group with inconsistent and conflicting results 
[11]. 
In a cross-sectional community-based study for the com-
parison of neurocognitive function in patients with SMI and 
in those with MCI in 84 Koreans, they identified the charac-
teristic differences in the neurocognitive domains of SMI and 
MCI. Cognitive deficits are found in both SMI and MCI, 
but the MCI group showed more distinctive deficits in de-
layed recall and recognition test of verbal learning and nam-
ing ability compared to the SMI group [18]. On the con-
trary, several observational studies have suggested that SMI 
is more associated with depression, anxiety, personality and 
education than cognitive decline [19]. A survey of 283 com-
munity-dwelling people aged 45 to 94 years revealed that 
combination of measures of personality, emotional distress, 
and health status explained about a third of the memory im-
pairment in America [20].
Brain CT and 18F-FDG PET has been recognized as a 
crucial diagnostic marker in MCI, supporting the presence or 
the exclusion of Alzheimer’s disease pathology. The typical 
temporo-parietal pattern suggested prodromal Alzheimer’s dis-
ease in several cases, some of them progressing to 
Alzheimer’s disease [21]. Our study also showed that the 
metabolism in temporal lobes and pariatal lobes tended to de-
crease in the AAMI group, and the context is the same as 
that in the attention domain.
Some mechanisms could explain the significant relationship 
between AAMI and MCI. The biomarkers that indicate 
Alzheimer’s disease are low in amyloid  1-42, increased in 
total tau and phosphorylated tau. According to some studies, 
this characteristic is seen in patients with MCI, in a inter-
mediate state between normal elderly and Alzheimer’s disease, 
and can be found in cerebrospinal fluid 5 to 10 years before 
the onset of dementia [22]. In addition, MCI is known to 
have several characteristics that indicate that it is a pre-advanced 
stage of Alzheimer’s disease in brain-induced neurofilament, 
brain-derived neurotrophic factor, and functional and amyloid 
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imaging [23].
AAMI is not significantly known to be associated with 
Alzheimer's disease, but also thought to be affected by several 
health factors, the most important mechanism of association 
with neurocognitive function is the insulin resistance. Although 
the pathophysiology of memory impairment is not fully un-
derstood, the epidemiological data suggest that brain insulin 
resistance flanks both cognitive decline and progressive neu-
ro-inflammation in neurodegenerative diseases [24]. Some ex-
perimental study also reported the role of insulin in spatial 
memory and inflammatory process within the hippocampus 
for memory regulation. This mechanism may affect overall 
neurodegenerative disease, it can be interpreted that it is the 
main cause of the AAMI stage characterizing difference in 
from MCI [25].
Importantly, our study had several limitations. First, it is a 
retrospective observational analysis of an existing database that 
limits causal inferences. Additional research is needed to elu-
cidate longitudinal associations. Second, since we included 
participants voluntarily visited a single health center for cog-
nitive function check-ups, there remains the possibility of se-
lection bias. Especially, the participants who undertaken the 
PET/CT only for memory loss, except for those without cog-
nitive impairment, do not have sufficient sample size. Despite 
these potential limitations, we provided the differences in neu-
rocognitive function of pre-dementia patients with imaging 
studies including brain PET/CT. 
In conclusion, there are differences in decreased foci of 
metabolism among normal, AAMI and MCI groups, Especially, 
a difference of metabolic decrease was observed in parietal 
lobe. In the MCI group, the deficit of neurocognitive func-
tion was the significant in attention, and showed a broader 
range of cognitive deficits than AAMI group. This result is 
not sufficient, but it can be regarded as the basis of a study 
to characterize AAMI and MCI. 
Cognitive decline and neuropathological deficit have been 
increased in the aging society, and the prevention and man-
agement of dementia is emerging issues for the huge socio-
economic cost burden of dementia. It is not only possible to 
effectively prevent dementia disease by characterizing AAMI 
and MCI, but also to improve lifestyle (exercise and dietary 
habits correction), diabetes, hypertension, and metabolic syn-
drome influencing general physical strength and psychological 
factors. The management of life style risk factors and chronic 
metabolic conditions would helpful to reduce medical ex-
penditures as well as improve the quality of life for the in-
dividual elderly.
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